Biodegradable CCK-receptor Targeted Nanoparticle for the Treatment of Cancer

Summary of the technology

- Targets cancer cells with CCK-B receptors, significantly impacting pancreatic cancer treatment
- Utilizes biodegradable, non-toxic nanoparticles for efficient siRNA delivery
- Offers potential for broader application across various cancers expressing similar receptors

Georgetown University

OVERVIEW

This technology introduces biodegradable nanoparticles designed to target cancer cells expressing the CCK-B receptor, which is particularly effective in pancreatic cancer treatment. These nanoparticles facilitate siRNA delivery, enabling specialized, targeted cancer treatment with the potential for higher efficacy and lower side effects than conventional therapies.

BACKGROUND

Focusing on the urgent need for effective treatments for hard-to-treat cancers like pancreatic cancer, this innovation represents a significant advancement in targeted cancer therapy. Its development is underpinned by rigorous scientific research and a strong patent position.

Benefit

●Provides a targeted approach to cancer therapy, potentially increasing treatment efficacy while reducing side effects.

●Opens new avenues for the treatment of cancers with CCK-B receptor expression, beyond pancreatic cancer.

●Enhances patient outcomes through precision medicine, aligning with current trends in oncology.

Market Application

●Primary application in treating pancreatic cancer, with potential expansion to other cancers such as lung, stomach, and colon cancers.

●Applicable in both therapeutic settings and as part of a comprehensive treatment regimen, including in combination with other therapies.

Publications

  • US Published Patent 11,696,922
  • Smith JP, Whitcomb DC, Matters GL, Brand RE, Liao J, Huang YJ, and Frazier ML. Distribution of the CCK-B receptor genotype between pancreatic cancer patients and controls and its impact on survival. Pancreas, 44: 236-242. PMID: 25469546.
  • Smith JP, Fonkoua LK, and Moody TW. The Role of Gastrin and CCK Receptors in Pancreatic Cancer and Other Malignancies. J. Biol. Sci 2016; 12(3): 283-291
  • Smith, Jill P; Cooper, Timothy K; McGovern, Christopher O et al. (2014) Cholecystokinin receptor antagonist halts the progression of pancreatic cancer precursor lesions and fibrosis in mice. Pancreas 43:1050-9
  • Smith, Jill P; Harms, John F; Matters, Gail L et al. (2012) A single nucleotide polymorphism of the cholecystokinin-B receptor predicts risk for pancreatic cancer. Cancer Biol Ther 13:164-74
  • Smith, Jill P; Liao, Jiangang; Matters, Gail L; McGovern, Christopher O; Gilius, Evan L et al. (2016)GermlineMutation of the CCK Receptor: A Novel Biomarker for Pancreas Cancer Clinical and Translational Gastroenterology (2016), e134; doi:10.1038/ctg.2015.61

Related Keywords

  • Micro- and Nanotechnology
  • Cytology, Cancerology, Oncology
  • Oncology
  • cancer
  • rna
  • therapy

About Georgetown University

Our mission is to advance GU’s innovations through strategic alliances and new venture creation, to facilitate the translation of research breakthroughs into tangible solutions, and to cultivate a dynamic and inclusive environment for entrepreneurship. We advance this mission in support of the GU community and for the benefit of society.

Georgetown University

Never miss an update from Georgetown University

Create your free account to connect with Georgetown University and thousands of other innovative organizations and professionals worldwide

Georgetown University

Send a request for information
to Georgetown University

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.

Help

Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support